Not Yet RecruitingPhase 2

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

United States90 participantsStarted 2025-03

Plain-language summary

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult kidney transplant patients. * No known contraindications to Dipyridamole Exclusion Criteria: * Contraindications to Dipyridamole. * Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

What they're measuring

Change in Serum Phosphorus Levels After Dipyridamole Administration

Timeframe: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio

Trial details

NCT IDNCT06824454

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03

View on ClinicalTrials.gov More Hypophosphatemia trials